A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.
about
Indicators of responsiveness to immune checkpoint inhibitorsThe HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A
P2860
A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.
description
2016 nî lūn-bûn
@nan
2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.
@ast
A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.
@en
type
label
A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.
@ast
A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.
@en
prefLabel
A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.
@ast
A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.
@en
P2093
P2860
P356
P1433
P1476
A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma
@en
P2093
Anita Giobbie-Hurder
Argyro Tsiaras
Carla Becerra
David E Fisher
Evisa Gjini
F Stephen Hodi
Nageatte Ibrahim
Scott J Rodig
Scott R Granter
P2860
P304
P356
10.1002/CAM4.862
P407
P577
2016-10-17T00:00:00Z